These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 38238944)

  • 21. Treatment of Liver Cancer.
    Liu CY; Chen KF; Chen PJ
    Cold Spring Harb Perspect Med; 2015 Jul; 5(9):a021535. PubMed ID: 26187874
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bibliometric study of immunotherapy for hepatocellular carcinoma.
    Li Z; Zhang Y; Zhang B; Guo R; He M; Liu ZL; Yang L; Wang H
    Front Immunol; 2023; 14():1210802. PubMed ID: 37600802
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Systemic treatment options of primary hepatocellular carcinoma].
    Dank M; Padányi P
    Magy Onkol; 2018 Mar; 62(1):53-61. PubMed ID: 29570187
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Advanced Hepatocellular Cancer: the Current State of Future Research.
    Connell LC; Harding JJ; Abou-Alfa GK
    Curr Treat Options Oncol; 2016 Aug; 17(8):43. PubMed ID: 27344158
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Systemic therapy of liver cancer.
    Demir T; Lee SS; Kaseb AO
    Adv Cancer Res; 2021; 149():257-294. PubMed ID: 33579425
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Selective internal radiation therapies for unresectable early-, intermediate- or advanced-stage hepatocellular carcinoma: systematic review, network meta-analysis and economic evaluation.
    Walton M; Wade R; Claxton L; Sharif-Hurst S; Harden M; Patel J; Rowe I; Hodgson R; Eastwood A
    Health Technol Assess; 2020 Sep; 24(48):1-264. PubMed ID: 33001024
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Clinical research progression of molecular-targeted drugs and PD-1 inhibitors for advanced hepatocellular carcinoma].
    Lai JM; Hu S; Lin H; Luo H; Luo YB
    Zhonghua Zhong Liu Za Zhi; 2019 Jun; 41(6):406-409. PubMed ID: 31216824
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Treatment of advanced hepatocellular carcinoma : Novel agents and role of local therapy].
    Parisod L; Duran R; Denys A; Digklia A
    Rev Med Suisse; 2017 May; 13(563):1032-1034. PubMed ID: 28636293
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Status and challenges of neoadjuvant immunotherapy for hepatocellular carcinoma].
    Xia YX; Cao HS; Tang WW; Wang XH
    Zhonghua Wai Ke Za Zhi; 2023 Jan; 61(1):7-12. PubMed ID: 36603877
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Molecular targeted therapy and immunotherapy in advanced hepatocellular carcinoma: a systematic review and Bayesian network meta-analysis based on randomized controlled trials.
    Zhang YL; Cui XJ; Xing H; Ning HF; Dong P; Wang GZ
    Ann Med; 2023; 55(2):2242384. PubMed ID: 37557186
    [TBL] [Abstract][Full Text] [Related]  

  • 31. ROS in hepatocellular carcinoma: What we know.
    Xing L; Tang Y; Li L; Tao X
    Arch Biochem Biophys; 2023 Aug; 744():109699. PubMed ID: 37499994
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Recent advances into the molecular mechanisms and therapeutic targeting of hepatocellular carcinoma.
    Chua MS; Wang L
    Anticancer Agents Med Chem; 2011 Jul; 11(6):491-2. PubMed ID: 21574957
    [No Abstract]   [Full Text] [Related]  

  • 33. [Regulatory effect of molecular targeted drugs on the immune system for liver cancer].
    Cheng X; Chen JZ; Guo YB
    Zhonghua Gan Zang Bing Za Zhi; 2021 Oct; 29(10):1031-1034. PubMed ID: 34814404
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hepatocellular carcinoma in the era of immunotherapy.
    Sim HW; Knox J
    Curr Probl Cancer; 2018; 42(1):40-48. PubMed ID: 29150141
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [A clinical study of targeted immunotherapy combined with hepatic arterial chemoembolization in the treatment of liver injury associated with primary liver cancer].
    Liu LD; Dong SM; Li YY; Nan YM
    Zhonghua Gan Zang Bing Za Zhi; 2023 Nov; 31(11):1156-1162. PubMed ID: 38238948
    [No Abstract]   [Full Text] [Related]  

  • 36. Hepatocellular carcinoma: systemic therapies and future perspectives.
    Mikhail S; Cosgrove D; Zeidan A
    Expert Rev Anticancer Ther; 2014 Oct; 14(10):1205-18. PubMed ID: 25199765
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Potentiality of immunotherapy against hepatocellular carcinoma.
    Tsuchiya N; Sawada Y; Endo I; Uemura Y; Nakatsura T
    World J Gastroenterol; 2015 Sep; 21(36):10314-26. PubMed ID: 26420958
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Advances in radiotherapy and immunity in hepatocellular carcinoma.
    Yang Y; Xiong L; Li M; Jiang P; Wang J; Li C
    J Transl Med; 2023 Aug; 21(1):526. PubMed ID: 37542324
    [TBL] [Abstract][Full Text] [Related]  

  • 39. PD-1 targeted immunotherapy for advanced hepatocellular carcinoma: current utilization and outcomes in the USA.
    Uhlig J; Stein S; Kim HS
    Future Oncol; 2022 May; 18(14):1691-1703. PubMed ID: 35172633
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Targeted therapies in hepatocellular carcinoma.
    Bronte F; Bronte G; Cusenza S; Fiorentino E; Rolfo C; Cicero G; Bronte E; Di Marco V; Firenze A; Angarano G; Fontana T; Russo A
    Curr Med Chem; 2014; 21(8):966-74. PubMed ID: 23992323
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.